戻る Agenda
Session 7 Track A, C: Use of Artificial Intelligence in Pharmacovigilance (PV)
Session Chair(s)
Vanessa Zapata
Associate Director, Regional Pharmacovigilance Officer
Merck Canada Inc., Canada
Lucye Galand, DVM, MBA, MSc
Acting Director, BGIVD, Therapeutic Products Directorate, HPFB
Health Canada, Canada
Marcia Bailey, BSN, MHS, RN
Safety Evaluation and Risk Management Scientific Director
GSK, Canada
Artificial Intelligence interest has been continuously increasing in the last few years,especially in the pharmacovigilance area. Some of its applications include Individual Case Safety Report process; Periodic Reporting; Aggregate Data; Signal Detection and Management and Risk Management. This session will give you an overview of where the Canadian regulator and industry are with a focus on specific initiatives that are currently implemented in the industry.
Learning Objective : At the conclusion of this session, participants should be able to:
- Identify the positive impact that AI can have on the PV day-to-day activities
- Understand Canadian Regulator expectations
- Identify areas of opportunity of Ai in PV for the future
Speaker(s)
Future perspectives in Pharmacovigilance - Artificial Intelligence or Intelligent Automation
Benny Ling, MSc
Health Canada, Canada
Senior Scientific Evaluator, Marketed Pharmaceuticals Bureau
Artificial Intelligence is Transforming Medical Value
Michael Moreyne, MBA
Merck, Canada
Associate Director Digital, Data & Analytics, Medical Affairs
Speaker
Oanh Dang, PharmD
FDA, United States
Pharmacotherapy Specialist, Regulatory Science Staff, OSE, CDER